Drug Sponsors

Royalty Pharma makes firm offer to acquire Elan

Tuesday, April 16, 2013 09:41 AM

Echo Pharma Acquisition (Royalty Pharma) announced the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan. 

More... »

BMS to spend $250M to expand biologics facility, create 350 jobs

Friday, April 12, 2013 10:43 AM

Bristol-Myers Squibb (BMS) is planning a $250 million expansion of its large-scale biologics manufacturing facility in Devens, Mass. The expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding approximately 350 employees to the Devens workforce over time.

More... »

Cleave Biosciences raises $10M in Series A Financing extension

Wednesday, April 10, 2013 11:13 AM

Cleave Biosciences has raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million. In conjunction with the financing, NEA partner Robert Garland, M.D., has joined Cleave's board of directors.

More... »

Unigene secures financing to extend operations, cuts 40% of staff

Tuesday, April 9, 2013 08:00 AM

Unigene Laboratories, a biopharmaceutical company focused on peptide-based therapeutics, has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors (VPC), whereby VPC has agreed to purchase an additional $750,000 senior secured note, providing Unigene with additional working capital.

More... »

Merz Pharma Group withdraws proposal to acquire Obagi

Monday, April 8, 2013 02:01 PM

Merz Pharma Group has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products for $22 per share in cash.

More... »

Bourne Partners, Covis Pharma acquire U.S. rights for five drugs from Sanofi

Monday, April 8, 2013 11:34 AM

Covis Pharma, a Switzerland-based specialty pharmaceutical company, has formed an agreement with Sanofi-Aventis and certain affiliates to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride) and Kayexalate (sodium polystyrene sulfate) in the U.S.  

More... »

Regeneron Pharmaceuticals to expand headquarters, create 400 jobs

Friday, April 5, 2013 11:07 AM

Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, N.Y., will expand its corporate headquarters and create more than 400 new high-skill jobs. 

More... »

Elan closes Tysabri collaboration transaction with Biogen Idec

Wednesday, April 3, 2013 03:17 PM

Elan, a biotechnology company based in Ireland, has closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec, which was originally announced on February 6, 2013.

More... »

MedImmune aquires Alphacore Pharma

Wednesday, April 3, 2013 02:20 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.

More... »

GSK publishes 2012 corporate responsibility report

Wednesday, April 3, 2013 10:18 AM

GlaxoSmithKline has published its Corporate Responsibility Report, in which it reiterates its commitment to operate responsibly, openly and transparently and outlines advances made on this agenda during 2012.

More... »